Allarity Therapeutics Inc (ALLR): Expect it to shoot to at least 1$ again...

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	260
Posts	13902
Boards Moderated	0
Alias Born	04/12/2007

Klinsmann

Re: S-BEES-BUMBLEBEE post# 149

Monday, 05/15/2023 4:04:02 AM

Monday, May 15, 2023 4:04:02 AM

Expect it to shoot to at least 1$ again near term...

Bullish

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent ALLR News

Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/10/2026 09:18:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 12:54:39 PM
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:02:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:22:50 PM
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 01:00:48 PM
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need • GlobeNewswire Inc. • 02/18/2026 01:15:00 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/12/2026 09:18:22 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:00:35 PM
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment • GlobeNewswire Inc. • 02/03/2026 01:00:00 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/29/2026 01:00:18 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 12:49:37 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:13:58 PM
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders • GlobeNewswire Inc. • 12/31/2025 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 02:21:54 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2025 02:16:37 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/08/2025 05:15:20 AM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/03/2025 02:11:40 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:00:59 PM
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 02:00:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2025 08:05:10 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/30/2025 09:17:29 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent ALLR News

More ALLR News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent ALLR News

Go Ad-Free